K-Ras and Dpc4 mutations in chronic pancreatitis: Case series

Croatian Medical Journal

Volumn 48, Issue 2, 2007, Pages 218-224

  Hadžija, Marijana Popović ^a   Korolija, Marina ^a   Razumović, Jasminka Jakić ^b   Pavković, Pajica ^c   Hadžija, Mirko ^a   Kapitanović, Sanja ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c University of Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DNA; K RAS PROTEIN; NUCLEOTIDE; PARAFFIN; PROTEIN P53; SMAD4 PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA EXTRACTION; DNA ISOLATION; DNA SEQUENCE; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

GENES, P53; GENES, RAS; HUMANS; MUTATION; PANCREATITIS, CHRONIC; SMAD4 PROTEIN;

EID: 34247492857     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bradley EL III. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586-90.
2. Hsiang D, Friess H, Buchler MW, Ebert M, Butler J, Korc M. Absence of K-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis. Am J Surg. 1997;173:242-6.
3. DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol. 2004;20:444-51.
4. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg. 2004;239:763-9.
5. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-72.
6. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg. 2003;186:279-86.
7. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902-12.
8. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141-5.
9. Whitcomb DC, Somogyi L. Lessons from hereditary pancreatitis. Croat Med J. 2001;42:484-7.
10. Kubrusly MS, Cunha JE, Bacchella T, Abdo EE, Jukemura J, Penteado S, et al. Detection of K-ras point mutation at codon 12 in pancreatic diseases: a study in a Brazilian casuistic. JOP. 2002;3:144-51.
11. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett. 1993;69:151-60.
12. Gansauge S, Schmid RM, Muller J, Adler G, Mattfeldt T, Beger HG. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg. 1998;85:337-40.
13. Luttges J, Diederichs A, Menke MA, Vogel I, Kremer B, Kloppel G. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer. 2000;88:2495-504.
14. Choudari CP, Imperiale TF, Sherman S, Fogel E, Lehman GA. Risk of pancreatitis with mutation of the cystic fibrosis gene. Am J Gastroenterol. 2004;99:1358-63.
15. Nollau P, Moser C, Weinland G, Wagener C. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer. 1996;66:332-6.
16. Popovic Hadzija M, Radosevic S, Kovacevic D, Lukac J, Hadzija M, Spaventi R, et al. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation. Mutat Res. 2004;548:61-73.
17. Weiss FU, Simon P, Mayerle J, Kraft M, Lerch MM. Germline mutations and gene polymorphism associated with human pancreatitis. Endocrinol Metab Clin North Am. 2006;35:289-302.
18. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330:1198-208.
19. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. Radiology. 2002;223:603-13.
20. Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Deviere J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy. 2004;36:535-42.
21. Queneau PE, Adessi GL, Thibault P, Cleau D, Heyd B, Mantion G, et al. Early detection of pancreatic cancer in patients with chronic pancreatitis: diagnostic utility of a K-ras point mutation in the pancreatic juice. Am J Gastroenterol. 2001;96:700-4.
22. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T, et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology. 2005;128:2124-30.
23. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowskal H, Strzelczyk J, Janiak A, et al. Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepatogastroenterology. 2006;53:608-12.
24. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol. 1993;142:1534-43.
25. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731-4.
26. Kallakury BV, Jennings TA, Ross JS, Breese K, Figge HL, Fisher HA, et al. Alteration of the p53 locus in benign hyperplastic prostatic epithelium associated with high-grade prostatic adenocarcinoma. Diagn Mol Pathol. 1994;3:227-32.
27. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, et al. p53 mutations in benign breast tissue. J Clin Oncol. 1995;13:2293-300.
28. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-84.
29. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res. 2004;10:1597-604.
30. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-6.
31. Inoue H, Furukawa T, Sunamura M, Takeda K, Matsuno S, Horii A. Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. Genes Chromosomes Cancer. 2001;31:295-9.
32. Luttges J, Galehdari H, Brocker V, Schwarte-Waldhoff I, Henne-Bruns D, Kloppel G, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol. 2001;158:1677-83.
33. Del Chiaro M, Boggi U, Presciuttini S, Bertacca L, Croce C, Mosca I, et al. Genetics of pancreatic cancer: where are we now? Where are we going? JOP. 2005;6(1 Suppl):60-7.
34. Costentin L, Pages P, Bouisson M, Berthelemy P, Buscail L, Escourrou J, et al. Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases. Pancreatology. 2002;2:17-25.